We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+7.19%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$811M
AUM Growth
+$71.2M
Cap. Flow
+$48M
Cap. Flow %
5.92%
Top 10 Hldgs %
28.89%
Holding
102
New
7
Increased
37
Reduced
34
Closed
10

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$18.2M
2
BDX icon
Becton Dickinson
BDX
+$16.8M
3
BMY icon
Bristol-Myers Squibb
BMY
+$14.2M
4
CELG
Celgene Corp
CELG
+$13M
5
CI icon
Cigna
CI
+$12.6M

Top Sells

Rank Stock Value
1
ADMS
Adamas Pharmaceuticals
ADMS
+$15.2M
2
NKTR icon
Nektar Therapeutics
NKTR
+$12.5M
3
ESPR
Esperion Therapeutics
ESPR
+$10.4M
4
COR icon
Cencora
COR
+$6.72M
5
UHS icon
Universal Health Services
UHS
+$5.94M

Sector Composition

Rank Sector Weight
1 Healthcare 94.68%
2 Technology 0.23%
3 Energy 0.22%
4 Financials 0.18%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELV icon
26
Elevance Health
ELV
$85.5B
$13.4M 1.65%
61,000
+30,000
+97% +$7.05M
INCY icon
27
Incyte
INCY
$24.4B
$13.2M 1.63%
158,963
-4,740
-3% -$427K
ABT icon
28
Abbott
ABT
$187B
$12.1M 1.49%
202,000
+80,000
+66% +$4.82M
REGN icon
29
Regeneron Pharmaceuticals
REGN
$80.8B
$11.7M 1.44%
34,000
+2,846
+9% +$990K
EW icon
30
Edwards Lifesciences
EW
$51.7B
$11.6M 1.43%
250,092
+30,000
+14% +$1.3M
BIIB icon
31
Biogen
BIIB
$30.7B
$11.6M 1.43%
42,300
+27,000
+176% +$8.38M
ARRY
32
DELISTED
Array Biopharma Inc
ARRY
$11.4M 1.41%
701,470
+198,411
+39% +$3.18M
ARNA
33
DELISTED
Arena Pharmaceuticals Inc
ARNA
$11.3M 1.39%
285,642
-100,000
-26% -$3.89M
AGN
34
DELISTED
Allergan plc
AGN
$10.1M 1.24%
60,000
+948
+2% +$159K
ALNY icon
35
Alnylam Pharmaceuticals
ALNY
$29.3B
$10M 1.23%
83,967
+25,000
+42% +$3.22M
BSX icon
36
Boston Scientific
BSX
$71.5B
$9.51M 1.17%
347,968
– –
NVCR icon
37
NovoCure
NVCR
$1.91B
$9.48M 1.17%
435,000
-32,569
-7% -$701K
NBIX icon
38
Neurocrine Biosciences
NBIX
$16.6B
$9.12M 1.12%
110,000
-7,969
-7% -$673K
XNCR icon
39
Xencor
XNCR
$1.55B
$8.99M 1.11%
300,000
-17,500
-6% -$458K
COR icon
40
Cencora
COR
$61.2B
$8.99M 1.11%
104,261
-70,000
-40% -$6.72M
PTLA
41
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$8.83M 1.09%
270,248
+59,095
+28% +$2.59M
LOXO
42
DELISTED
Loxo Oncology, Inc
LOXO
$8.65M 1.07%
75,000
-15,280
-17% -$1.63M
MYOK
43
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$8.21M 1.01%
168,272
-10,000
-6% -$520K
KYNB
44
Kyntra Bio
KYNB
$29.4M
$7.83M 0.97%
6,782
– –
AGIO icon
45
Agios Pharmaceuticals
AGIO
$1.93B
$7.77M 0.96%
95,000
-5,000
-5% -$386K
MGNX icon
46
MacroGenics
MGNX
$257M
$7.55M 0.93%
300,000
-8,604
-3% -$209K
CNC icon
47
Centene
CNC
$32.5B
$6.95M 0.86%
130,000
+40,000
+44% +$2.09M
SGEN
48
DELISTED
Seagen Inc. Common Stock
SGEN
$6.8M 0.84%
+130,000
New +$7.08M
RVNC
49
DELISTED
Revance Therapeutics, Inc.
RVNC
$6.26M 0.77%
203,181
+20,601
+11% +$663K
IMMU
50
DELISTED
Immunomedics Inc
IMMU
$6.07M 0.75%
415,330
-65,000
-14% -$1.06M
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2018 Portfolio in Review

As of Q1 2018, Rhenman & Partners Asset Management held 102 positions worth $811M, up 9.6% from $740M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $48M of net new capital in Q1 2018, opening 7 new positions and adding to 37 existing holdings. Its largest new stake was CVS Health: 253,868 shares worth $15.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 90% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Adamas Pharmaceuticals, an estimated $15.2M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2018 buy was CVS Health: 253,868 shares worth $15.8M.
  • Rhenman & Partners Asset Management added most to Bristol-Myers Squibb in Q1 2018, an estimated $14.2M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2018 reduction was Adamas Pharmaceuticals, cutting an estimated $15.2M.
  • Rhenman & Partners Asset Management fully exited Universal Health Services in Q1 2018, selling an estimated $5.94M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $811M portfolio in Q1 2018.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 10 in Q1 2018.
  • Rhenman & Partners Asset Management's portfolio value rose 9.6% quarter-over-quarter to $811M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2018, filed 11 Apr 2018.